Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aptevo Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology company developing immune-oncology candidates based on ADAPTIR and ADAPTIR-FLEX platforms. Its 8-K reports record clinical updates for mipletamig in acute myeloid leukemia, annual financial results, material agreements, executive and board changes, and other public-company events.
The company’s proxy and registration filings disclose shareholder voting matters, proposed charter and administrative amendments, Nasdaq share-issuance approvals, common-stock financing arrangements, and capital-structure information related to its standby equity purchase agreement. These filings also provide formal context for governance, securities issuance mechanics, and the funding disclosures associated with Aptevo’s oncology pipeline.
Aptevo Therapeutics Inc. (NASDAQ: APVO) has filed a Rule 424(b)(4) prospectus for a registered direct offering that could raise gross proceeds of up to $8.0 million. The company will sell 2,105,000 shares of common stock and 360,000 pre-funded warrants (in lieu of shares for investors breaching beneficial-ownership limits), each bundled with five five-year common warrants, resulting in 12,325,000 common warrants overall. Every warrant carries a $3.25 exercise price but is exercisable only after required stockholder approval; without such approval the warrants have no value.
The combined offering price is $3.25, a ~37% discount to the June 18 2025 closing price of $5.13. If fully subscribed, the breakdown is as follows:
- Gross proceeds: $8,011,250
- Placement-agent fee (7%): $560,788
- Estimated company expenses (ex-fee): $275,000
- Net proceeds before expenses: $7,450,463
There is no escrow or minimum; the deal may close for any amount up to the maximum and terminates no later than June 30 2025. Roth Capital Partners is acting on a best-efforts basis and will not purchase the securities. Neither the common nor pre-funded warrants will be listed, limiting liquidity.
The offering magnifies potential dilution: including the underlying shares, up to 12.685 million additional shares (exclusive of warrant coverage) could ultimately be issued. Share, price, and warrant data reflect the 1-for-20 reverse split completed on May 23 2025.
Use-of-proceeds specifics are not provided in the excerpt, but investors are directed to the prospectus section for risk factors, capitalization, dilution analysis, and Nasdaq compliance considerations.